Published in Vaccine Weekly, November 30th, 1998
Joseph E. Blaney Jr., Satvir S. Tevethia, and colleagues of Pennsylvania State University, Hershey, Pennsylvania, report experiments in which mice were vaccinated with genetically engineered adenovirus expressing a single major histocompatibility complex (MHC) class I-restricted CTL recognition epitope cross reactive for HSV-2 and HSV-1. The mice then were intranasally challenged with a lethal dose of HSV-2.
"Development of the ... CTL response conferred resistance in 60 to 75 percent of mice...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly